Revance Therapeutics reported $-77484000 in Operating Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Abbvie ABBV:US USD 4.6B 1.31B
Aerie Pharmaceuticals AERI:US USD -26672000 8.54M
ALKERMES ALKS:US USD -60641000 26.18M
Bristol Myers Squibb BMY:US USD 2.47B 117M
Cara Therapeutics CARA:US USD -23845000 19.37M
Coherus Biosciences CHRS:US USD -80449000 36.44M
Eli Lilly And LLY:US USD 1.68B 466.4M
Endo International Ordinary Shares ENDP:US USD -636822000 1.1B
Horizon Pharma HZNP:US USD 160.61M 72.05M
Johnson & Johnson JNJ:US USD 5.82B 18M
Merk MRK:US USD 3.99B 939M
Neurocrine Biosciences NBIX:US USD 87.8M 103.1M
Pacira Pharmaceuticals PCRX:US USD 21.29M 9.95M
Procter & Gamble PG:US USD 4.94B 1.34B
Revance Therapeutics RVNC:US USD -77484000 19.64M
Supernus Pharmaceuticals SUPN:US USD -1523000 12.87M
Teva Pharmaceutical Industries TEVA:US USD 419M 1.37B